Liver Testing Through a New Investigative Tool

hepquant liver test

HepQuant’s innovative, noninvasive tests of liver function and physiology provide patients, investigators, care providers, and payers with a dynamic and comprehensive Picture of Liver Health.
hepquant test acinus

HepQuant’s innovative, noninvasive tests of liver function and physiology provide patients, investigators, care providers, and payers with a dynamic and comprehensive Picture of Liver Health.

HepQuant’s innovative, noninvasive tests of liver function and physiology provide patients, investigators, care providers, and payers with a dynamic and comprehensive Picture of Liver Health.
hepquant liver test

HepQuant’s innovative, noninvasive tests of liver function and physiology provide patients, investigators, care providers, and payers with a dynamic and comprehensive Picture of Liver Health.
hepquant test acinus

HepQuant’s innovative, noninvasive tests of liver function and physiology provide patients, investigators, care providers, and payers with a dynamic and comprehensive Picture of Liver Health.

HepQuant’s innovative, noninvasive tests of liver function and physiology provide patients, investigators, care providers, and payers with a dynamic and comprehensive Picture of Liver Health.

Liver Function Tests

Breaking Through Conventional Thinking About Liver Health Testing

HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.

Recent Publications

NASH Summit 

HepQuant at NASH Conference 2019

Upcoming Events

HepQuant will be attending / presenting at the following local, national or international meetings:

♦  Bavino 7 Consensus Workshop – Personalized Care in Portal Hypertension | October 27-30 | Sponsor

♦  AASLD The Liver Meeting | November 12-15

  • Poster: The HepQuant SHUNT Test Predicts the Likelihood of Finding Esophageal Varices and Particularly Large Varices at Endoscopy. Shiffman ML, Leise MD, Reddy KR, Hellstern PA, Hassanein T, Qureshi K, Mena E, Smith AD, Kittelson JM, Helmke SM, Everson GT, HepQuant, and SHUNT-V Investigators Group.
  • Oral Presentation: Treatment with HMG-CoA Reductase Inhibitors (Statins) is Associated with Preservation of Hepatic Function in Advanced Chronic Liver Disease (CLD): Results from the SHUNT-V Study. Rahimi RS, Lucas KJ, Weinberg EM, Kayali Z, Bhagat VK, Keaveny AP, Mantry PS, Smith AD, Kittelson JM, Helmke SM, Everson GT, and SHUNT-V Investigators Group.
  • Poster: BI 685509 Improves Hepatic Function in Subjects with Child-Pugh A Cirrhosis and a Liver Stiffness Measurement of >15 KPA: Results from the HepQuant SHUNT Test. Lawitz EJ, Ertle J, Schoelch C, Gawshaw I, Helmke SM and Everson GT. – (Poster Presentation at AASLD, The Liver Meeting 2021)

♦  American Heart Association (AHA) Annual Meeting | November 13-15

  • Oral Presentation: Clinical and Laboratory Correlates of Impaired Cholate Clearance in the Adult Fontan.  Kim YY, Saef J, Everson G, Helmke S, Carducci J, Glatz AC, Partington SL, Ruckdeschel E, Rychik J, Hoteit MA.

♦  NASH Summit 2021 | November 29-December 2 | Sponsor

  • Oral Presentation: HepQuant: Progressing towards a Sensitive and Reliable Endpoint for Treatment Efficacy.  Greg Everson, MD.
    • New Data from Clinical Trials (response to new pharma therapy, reproducibility, progression to decomp in cirrhosis, portal hypertension) 
    • Pivotal Study and Regulatory Progress
    • Anticipated Timelines for Clinical Trial and Commercial Scale-up

CONTACT US

HepQuant CEO Greg Everson joined Proactive at the Biotech Showcase 2020 in San Francisco, Jan. 14th, 2020.

Recent Events

EASL International Liver Congress | June 23-26, 2021

AASLD/FDA DILI Conference Drug Induced Liver Injury | Virtual Conference | April 20 – 22, 2021 | “New Developments, Innovative Tools and Assessment Strategies in Patients with Underlying Liver Disease or Cancer and in the Setting of the Covid-19 Pandemic” | Gregory T. Everson, MD, FAASLD presented “Non-invasive Quantitative Liver Tests for Disease Activity and Fibrosis: Can They Reliably Guide Optimal Treatment Regimens During the Progression of CLD.”

  • Poster: The Disease Severity Index (DSI) from the HepQuant SHUNT Test Sets the Stage for Predicting Drug Pharmacokinetics (PK) in Chronic Liver Disease

2021 NASH TAG Conference | March 11-13, 2021 | Attended by Gregory T. Everson, MD and Brad Everson, CBDO

AASLD: The Liver Meeting Digital Experience | November 13-16, 2020 | Conference Website

  • Poster: The HepQuant SHUNT Test of Global Liver Function and Physiology Identifies the Patients with Advanced Fibrosis or Compensated Cirrhosis Who are At-Risk for Hepatocellular Carcinoma
  • Poster: Diagnostic Performance of The HepQuant Shunt Test in Prediction of Large Esophageal Varices in Well-Compensated Fibrosis or Cirrhosis Due to Chronic Hep C

Oral Presentation by Baylor – AASLD: The Liver Meeting Digital Experience | November 13-16, 2020

  • Presentation: “Dual Cholate Test and Prediction of Decompensation, Liver Transplantation, Death and Hospitalization in Cirrhosis: A Prospective Study.

These images and links are for informational purposes only and do not imply that HepQuant has any formal relationships with the organizations, nor do the organizations endorse HepQuant or its liver function tests.